KRAS is of tremendous interest in oncology because KRAS mutations occur in 22% of all tumours, including 61% of pancreas, 33% of colon and 17% of lung cancers [39], 3 of the 5 most lethal cancers world-wide [40]. This evidence concerns the gene KRAS and neoplasm.